Ying Yu, Yan Chen, Long Ma, You-Yang Qu, Yu-Nong Li, Ying Peng, Yu-Lan Zhu, Jia He, Hai-Yan Gou, Yan-Mei Zhu
{"title":"阿戈美拉汀联合认知行为疗法治疗年轻人延迟睡眠-觉醒期障碍的疗效:一项随机对照研究。","authors":"Ying Yu, Yan Chen, Long Ma, You-Yang Qu, Yu-Nong Li, Ying Peng, Yu-Lan Zhu, Jia He, Hai-Yan Gou, Yan-Mei Zhu","doi":"10.1080/15402002.2022.2136178","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Delayed sleep-wake phase disorder (DSWPD) is common and easily misdiagnosed in young people, and to date, there is no evidence-based treatment.</p><p><strong>Purpose: </strong>A nonblinded randomized controlled study evaluated the effect of agomelatine therapy (AT) and cognitive behavior therapy (CBT) on DSWPD in young adults.</p><p><strong>Methods: </strong>Sixty adolescents and young adults (range = 19-24 years, mean = 22 years, 52% female) diagnosed with DSWPD were randomized to receive 4 weeks of agomelatine therapy with or without cognitive behavior therapy. Sleep diaries, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Insomnia Severity Index (ISI), and World Health Organization wellbeing questionnaire (WHO-5) were measured pre-treatment and post-treatment.</p><p><strong>Results: </strong>Agomelatine therapy for 4 weeks shifted the sleep-wake rhythm (<i>p</i> < .001) forward in both groups at the week 4 assessment. There were no significant differences in sleep onset (<i>p</i> = .099) and sleep offset (<i>p</i> = .959) between the CBT group and the no treatment (NT) group at the follow-up visits. However, significant differences were found in sleep duration (<i>p</i> = .002), sleep quality (<i>p</i>=0.005), sleep difficulties (<i>p </i>< .001), daytime sleepiness (<i>p</i> = .001), and wellbeing (<i>p</i> = .007) between groups.</p><p><strong>Conclusions: </strong>The improvements were received largely through the sleep-promoting effects of agomelatine therapy, and combining with cognitive behavior therapy on maintenance of altered sleep rhythms might be feasible.</p>","PeriodicalId":55393,"journal":{"name":"Behavioral Sleep Medicine","volume":"21 5","pages":"529-539"},"PeriodicalIF":2.2000,"publicationDate":"2023-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of agomelatine with cognitive behavioral therapy for delayed sleep-wake phase disorder in young adults: A randomized controlled study.\",\"authors\":\"Ying Yu, Yan Chen, Long Ma, You-Yang Qu, Yu-Nong Li, Ying Peng, Yu-Lan Zhu, Jia He, Hai-Yan Gou, Yan-Mei Zhu\",\"doi\":\"10.1080/15402002.2022.2136178\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Delayed sleep-wake phase disorder (DSWPD) is common and easily misdiagnosed in young people, and to date, there is no evidence-based treatment.</p><p><strong>Purpose: </strong>A nonblinded randomized controlled study evaluated the effect of agomelatine therapy (AT) and cognitive behavior therapy (CBT) on DSWPD in young adults.</p><p><strong>Methods: </strong>Sixty adolescents and young adults (range = 19-24 years, mean = 22 years, 52% female) diagnosed with DSWPD were randomized to receive 4 weeks of agomelatine therapy with or without cognitive behavior therapy. Sleep diaries, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Insomnia Severity Index (ISI), and World Health Organization wellbeing questionnaire (WHO-5) were measured pre-treatment and post-treatment.</p><p><strong>Results: </strong>Agomelatine therapy for 4 weeks shifted the sleep-wake rhythm (<i>p</i> < .001) forward in both groups at the week 4 assessment. There were no significant differences in sleep onset (<i>p</i> = .099) and sleep offset (<i>p</i> = .959) between the CBT group and the no treatment (NT) group at the follow-up visits. However, significant differences were found in sleep duration (<i>p</i> = .002), sleep quality (<i>p</i>=0.005), sleep difficulties (<i>p </i>< .001), daytime sleepiness (<i>p</i> = .001), and wellbeing (<i>p</i> = .007) between groups.</p><p><strong>Conclusions: </strong>The improvements were received largely through the sleep-promoting effects of agomelatine therapy, and combining with cognitive behavior therapy on maintenance of altered sleep rhythms might be feasible.</p>\",\"PeriodicalId\":55393,\"journal\":{\"name\":\"Behavioral Sleep Medicine\",\"volume\":\"21 5\",\"pages\":\"529-539\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2023-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Behavioral Sleep Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/15402002.2022.2136178\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Behavioral Sleep Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15402002.2022.2136178","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Efficacy of agomelatine with cognitive behavioral therapy for delayed sleep-wake phase disorder in young adults: A randomized controlled study.
Background: Delayed sleep-wake phase disorder (DSWPD) is common and easily misdiagnosed in young people, and to date, there is no evidence-based treatment.
Purpose: A nonblinded randomized controlled study evaluated the effect of agomelatine therapy (AT) and cognitive behavior therapy (CBT) on DSWPD in young adults.
Methods: Sixty adolescents and young adults (range = 19-24 years, mean = 22 years, 52% female) diagnosed with DSWPD were randomized to receive 4 weeks of agomelatine therapy with or without cognitive behavior therapy. Sleep diaries, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Insomnia Severity Index (ISI), and World Health Organization wellbeing questionnaire (WHO-5) were measured pre-treatment and post-treatment.
Results: Agomelatine therapy for 4 weeks shifted the sleep-wake rhythm (p < .001) forward in both groups at the week 4 assessment. There were no significant differences in sleep onset (p = .099) and sleep offset (p = .959) between the CBT group and the no treatment (NT) group at the follow-up visits. However, significant differences were found in sleep duration (p = .002), sleep quality (p=0.005), sleep difficulties (p < .001), daytime sleepiness (p = .001), and wellbeing (p = .007) between groups.
Conclusions: The improvements were received largely through the sleep-promoting effects of agomelatine therapy, and combining with cognitive behavior therapy on maintenance of altered sleep rhythms might be feasible.
期刊介绍:
Behavioral Sleep Medicine addresses behavioral dimensions of normal and abnormal sleep mechanisms and the prevention, assessment, and treatment of sleep disorders and associated behavioral and emotional problems. Standards for interventions acceptable to this journal are guided by established principles of behavior change. Intending to serve as the intellectual home for the application of behavioral/cognitive science to the study of normal and disordered sleep, the journal paints a broad stroke across the behavioral sleep medicine landscape. Its content includes scholarly investigation of such areas as normal sleep experience, insomnia, the relation of daytime functioning to sleep, parasomnias, circadian rhythm disorders, treatment adherence, pediatrics, and geriatrics. Multidisciplinary approaches are particularly welcome. The journal’ domain encompasses human basic, applied, and clinical outcome research. Behavioral Sleep Medicine also embraces methodological diversity, spanning innovative case studies, quasi-experimentation, randomized trials, epidemiology, and critical reviews.